MedTrace Logo

Omega 3 Polyunsaturated Fatty Acids (PUFA) or Magnesium in Obese Polycystic Ovary Syndrome Patients

NCT02521753 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 123

Last updated 2025-04-01

No results posted yet for this study

Summary

Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder in reproductive age women. PCOS is usually characterized by an excessive androgen production, menstrual irregularities, and polycystic ovaries. Women with PCOS are often obese and have a varying degree of insulin resistance (IR). Weight reduction constitutes the initial treatment for these patients. Metformin has proven to be useful in IR and is frequently used in PCOS. However metformin use may be accompanied by gastrointestinal discomfort, and a high abandon rate. Other therapeutic alternatives such as magnesium and polyunsaturated fatty acids have been used in other IR states and may be useful in PCOS. The aim of this study is to asses the efficacy of these alternatives in obese PCOS patients.

Conditions

  • Polycystic Ovary Syndrome
  • Obesity

Interventions

DRUG

Metformin

Intervention also includes weight reduction diet and exercise therapy

DIETARY_SUPPLEMENT

Magnesium

Intervention also includes weight reduction diet and exercise therapy

DIETARY_SUPPLEMENT

PUFA

Intervention also includes weight reduction diet and exercise therapy

Sponsors & Collaborators

  • Coordinación de Investigación en Salud, Mexico

    lead OTHER_GOV

Principal Investigators

  • Mardia Guadalupe López Alarcón, MD, phD · Instituto Mexicano del Seguro Social

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
38 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2020-08-31
Completion
2025-03-31

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02521753 on ClinicalTrials.gov